Literature DB >> 32601970

Activation of mitochondrial unfolded protein response is associated with Her2-overexpression breast cancer.

Fang-Ming Chen1,2,3,4, Li-Ju Huang5, Fu Ou-Yang1,2, Jung-Yu Kan1,2, Li-Chun Kao1,2, Ming-Feng Hou6,7,8,9.   

Abstract

PURPOSE: Mitochondrial unfolding protein are abundant in breast cancer cells, but the mechanism by which breast cancer cells resist apoptosis is still not fully elucidated. In this study, we explored the role of mitochondrial unfolded protein response (mtUPR)-related proteins in four types of breast cancer tissues.
METHODS: Mitochondrial fractions were taken from four breast cancer tissues (luminal A, luminal B, Her2 -overexpression, and TNBC) and the expression of mitochondrial polyubiquitinated proteins was observed by western blot and ELISA. In addition, the expression of hsp10, hsp60, and clpp in mitochondria was observed by western blot in breast cancer tissues and adjacent tissues, and confirmed by ELISA. The expression levels of hsp10 and hsp60 were correlated with clinicopathological parameters in 114 breast cancer patients.
RESULTS: We found an increase in the performance of mitochondrial polyubiquitinated proteins in breast cancer tissues of luminal A, luminal B, Her2-overexpression, and TNBC. The mitochondrial hsp10, hsp60, and clpp are abundantly expressed in breast cancer tissues rather than adjacent noncancerous tissues. The expression levels of mitochondrial hsp10 and hsp60 were highest in histological grade 3 breast cancer tissues. Additionally, mitochondria with high hsp60 expression were more present in Her2-positive tumors.
CONCLUSIONS: We observed that mtUPR was specifically activated in breast cancer tissues but inactivated in normal mammary tissue. MtUPR had also exhibited a particular increase in Her2-overexpression tumors but not in ER- or PR-positive tumors. Taken together, we suggested that mtUPR may act as a potential candidate for developing novel Her2-overexpression breast cancer therapy.

Entities:  

Keywords:  Breast cancer‧mitochondrial unfolded protein response; Her2-overexpression; mtUPR

Year:  2020        PMID: 32601970     DOI: 10.1007/s10549-020-05729-9

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  5 in total

1.  Investigation of the effects of downregulation of jumping translocation breakpoint (JTB) protein expression in MCF7 cells for potential use as a biomarker in breast cancer.

Authors:  Madhuri Jayathirtha; Anca-Narcisa Neagu; Danielle Whitham; Shelby Alwine; Costel C Darie
Journal:  Am J Cancer Res       Date:  2022-09-15       Impact factor: 5.942

2.  Revealing molecular pathways for cancer cell fitness through a genetic screen of the cancer translatome.

Authors:  Duygu Kuzuoglu-Ozturk; Zhiqiang Hu; Martina Rama; Emily Devericks; Jacob Weiss; Gary G Chiang; Stephen T Worland; Steven E Brenner; Hani Goodarzi; Luke A Gilbert; Davide Ruggero
Journal:  Cell Rep       Date:  2021-06-29       Impact factor: 9.423

Review 3.  Insight into the mitochondrial unfolded protein response and cancer: opportunities and challenges.

Authors:  Ge Wang; Yumei Fan; Pengxiu Cao; Ke Tan
Journal:  Cell Biosci       Date:  2022-02-18       Impact factor: 7.133

4.  Knockdown of nuclear receptor binding SET domain-containing protein 1 (NSD1) inhibits proliferation and facilitates apoptosis in paclitaxel-resistant breast cancer cells via inactivating the Wnt/β-catenin signaling pathway.

Authors:  Yi Chen; Xiao Li; Jin Xu; Hua Xiao; Cuiju Tang; Wei Liang; Xuedan Zhu; Yueyu Fang; Hanjin Wang; Junfeng Shi
Journal:  Bioengineered       Date:  2022-02       Impact factor: 3.269

5.  SIRT3-mediated mitochondrial unfolded protein response weakens breast cancer sensitivity to cisplatin.

Authors:  Hao Chen; Dong-Ming Zhang; Zhi-Ping Zhang; Ming-Zhang Li; Hai-Feng Wu
Journal:  Genes Genomics       Date:  2021-08-02       Impact factor: 1.839

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.